Home Featured Page 238

Featured

Latest

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

Former Compass Interim Clinical Sciences Director Joins Clerkenwell Health as CMO

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental...

Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business...

Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation...

Understanding ‘Spiritual Emergency’ in the Context of Psychedelics

atai Life Sciences Increases Loan in Principal by US$6m to Support...

Small Pharma Announces Engagement of Investor Relations Provider

Fear of Death Impacts Quality of Life-How Psychedelics Can Help

PT262 – Carlene MacMillan, M.D. – Set, Setting, and Systems: Adding...

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment...

EDITOR PICKS

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit...

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

Former Compass Interim Clinical Sciences Director Joins Clerkenwell Health as CMO

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental...

Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business...

Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation...

Understanding ‘Spiritual Emergency’ in the Context of Psychedelics

atai Life Sciences Increases Loan in Principal by US$6m to Support...

Small Pharma Announces Engagement of Investor Relations Provider

Fear of Death Impacts Quality of Life-How Psychedelics Can Help

PT262 – Carlene MacMillan, M.D. – Set, Setting, and Systems: Adding...

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment...

EDITOR PICKS

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit...

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY